BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

The FDA granted Priority Review to an oral targeted therapeutic option for children with achondroplasia, setting a PDUFA target action date of February 4, 2027. The designation highlights significant unmet need; the article provides no drug or company name and reports no market reaction.